U.S. Non-alcoholic Steatohepatitis Biomarkers (Serum, Hepatic Fibrosis, Apoptosis) Market Research 2024-2030: Increasing Prevalence of Obesity, Type 2 Diabetes, and Metabolic Syndrome Fueling Demand
24 juil. 2024 09h15 HE
|
Research and Markets
Dublin, July 24, 2024 (GLOBE NEWSWIRE) -- The "U.S. Non-alcoholic Steatohepatitis Biomarkers Market Size, Share & Trends Analysis Report by Type (Serum, Hepatic Fibrosis, Apoptosis), End-use...
Nacuity Pharmaceuticals Announces First Patients Implanted in Final Cohort of Phase 1/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression
30 avr. 2024 09h00 HE
|
Nacuity Pharmaceuticals, Inc.
Two patients have been implanted in the final cohort of the trial Final cohort is actively enrolling adult patients undergoing vitrectomy FORT WORTH, Texas, April 30, 2024 (GLOBE NEWSWIRE) --...
Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr.
16 avr. 2024 09h00 HE
|
Nacuity Pharmaceuticals, Inc.
FORT WORTH, Texas, April 16, 2024 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel treatments for retinitis pigmentosa, cataract, and...
Nacuity Pharmaceuticals Announces Expansion of its Business Advisory Board with Appointment of Rare Disease Advocate Daniel Feller
14 févr. 2024 09h00 HE
|
Nacuity Pharmaceuticals, Inc.
FORT WORTH, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other...
Nacuity Pharmaceuticals Advances Phase 1/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression
11 juil. 2023 09h00 HE
|
Nacuity Pharmaceuticals, Inc.
New clinical site added and early safety signals observed in trial for treatment of ocular disease caused by oxidative stress First cohort is expected to achieve full enrollment by third quarter...
Nacuity Pharmaceuticals Achieves Target Enrollment for Phase 1/2 Clinical Trial of NPI-001 for the Treatment of Retinitis Pigmentosa Associated with Usher Syndrome
31 mai 2023 09h00 HE
|
Nacuity Pharmaceuticals, Inc.
Phase 1/2 SLO-RP trial completed target enrollment of 48 patients diagnosed with RP associated with USH Interim efficacy data anticipated by year end 2023 FORT WORTH, Texas, May 31, 2023 (GLOBE...
Global Nonalcoholic Steatohepatitis (NASH) Diagnostics Market Outlook to 2035
12 mai 2023 05h03 HE
|
Research and Markets
Dublin, May 12, 2023 (GLOBE NEWSWIRE) -- The "Global Nonalcoholic Steatohepatitis (NASH) Diagnostics Market Outlook to 2035" report has been added to ResearchAndMarkets.com's offering. The market...
Insights on the Cardiac Biomarkers Global Market to 2027
08 févr. 2023 06h18 HE
|
Research and Markets
Dublin, Feb. 08, 2023 (GLOBE NEWSWIRE) -- The "Cardiac Biomarkers: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. This report summarizes the global...
Cellular Health Screening Market Report 2022: Growth in the Adoption of Direct-To-Consumer Approach for the Availability of Kits Boosting Sector
24 oct. 2022 05h13 HE
|
Research and Markets
Dublin, Oct. 24, 2022 (GLOBE NEWSWIRE) -- The "Cellular Health Screening Market Size, Share & Trends Analysis Report by Test Type (Single Test Panels, Multi-test Panels), by Sample Type (Blood,...
Conagen unveils commercial production of high-purity non-GMO salidroside
27 sept. 2022 04h00 HE
|
Conagen
Bedford, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Conagen announced the commercialization of its 99% high-purity salidroside made by bioconversion technology, an active ingredient from the herbal...